Sight Sciences to Report Second Quarter 2021 Financial Results on August 12, 2021
Sight Sciences, Inc. (Nasdaq: SGHT) will announce its financial results for Q2 2021 on August 12, 2021, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Sight Sciences, Inc. (Nasdaq: SGHT) will announce its financial results for Q2 2021 on August 12, 2021, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET to discuss these results. The company focuses on developing medical devices aimed at prevalent eye diseases, currently marketing the OMNI® and TearCare® systems. Investors can access the conference call via a live and archived webcast on the company's investor relations website.
Positive
- Focused on developing proprietary medical devices for eye diseases.
- Currently markets two products: OMNI® Surgical System and TearCare® System.
Negative
- None.
Details
News Market Reaction – SGHT
The recorded move for SGHT in the trading session of this news was +2.66%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MENLO PARK, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) today announced it will report financial results for the second quarter 2021 after the market close on Thursday, August 12, 2021. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at https://investors.sightsciences.com/.
About Sight Sciences
Founded in 2011, Sight Sciences is a growth stage medical device company focused on the development and commercialization of proprietary devices that target the underlying causes of the world’s most prevalent eye diseases. The company currently markets two products, the OMNI® Surgical System and the TearCare® System. For more information, visit www.sightsciences.com.
OMNI® and TearCare® are registered trademarks of Sight Sciences.
© 2021 Sight Sciences. All rights reserved.
Media contact:
Shay Smith
Health+Commerce
707.971.9779
shay@healthandcommerce.com
Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.